Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company's IND Application
Does this $hitty stock action make sense? Hell no who can argue that?
However this is when you load up and wait until PH1 because that was dang good news for an emerging bio startup with AI tech that treats LUNG CANCER tumors >> JMHO << but I've done a ton of DD on this just wait a storm is coming...
IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second Quarter of this Year, Respectively
Kiromic BioPharma, Inc.
The histopathology report, authored by a certified veterinary pathologist, revealed no adverse microscopic findings related to the administration of Deltacel™ alone or as part of the combination treatment.
"We're pleased to receive a clean pharmacology profile with no adverse findings and are encouraged by the preclinical results to-date in support of our planned IND submission. This histopathology report includes results from more than 500 histological sections from multiple organs of mice treated with Deltacel™, with the combination treatment of Deltacel™ and a non-biological anti-tumor therapy, or mice left untreated. This study completes the necessary dataset for authoring the Pharmacology Report of the Efficacy Study, which is an essential component of the nonclinical module of our IND application," stated Leonardo Mirandola, Ph.D., Chief Scientific Officer of Kiromic BioPharma.
"These findings are in line with what we observed in a study evaluating Deltacel™ monotherapy at a dose more than 7 times higher than the maximum dose planned for the Deltacel™ clinical trial, and they confirm that Deltacel™ was well tolerated in mice, even when given as part of a combination therapy that further boosted its potency," continued Dr. Mirandola. "Kiromic plans to submit the Deltacel™ IND application to the U.S. FDA in this first quarter, and if accepted, plans to begin the activation of the clinical trial process in the second quarter of 2023. The planned clinical study will evaluate Deltacel™ in combination with a non-biological anti-tumor therapy for the treatment of non-small cell lung cancer."
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to detect, develop, and commercialize cell therapies with a therapeutic focus on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid cancers. Kiromic's DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.
https://www.businesswire.com/news/home/20230228005440/en/Kiromic-BioPharma-Reports-Favorable-Deltacel%E2%84%A2-Preclinical-Pharmacology-Results
Recent KRBP News
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients • Business Wire • 04/24/2024 12:08:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/19/2024 08:30:26 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 04/10/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/05/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2024 08:30:20 PM
- Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial • Business Wire • 04/02/2024 12:18:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/21/2024 09:21:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2024 09:58:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2024 09:57:02 PM
- Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial • Business Wire • 03/19/2024 12:08:00 PM
- Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial • Business Wire • 03/01/2024 01:08:00 PM
- Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th • Business Wire • 02/28/2024 11:30:00 PM
- Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th • GlobeNewswire Inc. • 02/28/2024 09:09:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:30:45 PM
- Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months • Business Wire • 02/14/2024 01:08:00 PM
- Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer • Business Wire • 01/29/2024 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:15:21 PM
- Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial • Business Wire • 01/05/2024 01:08:00 PM
- Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer • Business Wire • 12/14/2023 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:49:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 08:45:22 PM
- Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14 • Business Wire • 09/13/2023 08:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:15:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/15/2023 08:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:52:28 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM